• Clasto-Lactacystin β-lactone: Precision Proteasome Inhibitor

  2026-05-15

  Clasto-Lactacystin β-lactone delivers unparalleled specificity as an irreversible, cell-permeable proteasome inhibitor—enabling robust ubiquitin-proteasome pathway research in cancer, neurodegeneration, and viral immunity. This guide translates landmark mechanistic insights and experimental strategies into actionable protocols and troubleshooting tips, maximizing the impact of your proteasome inhibition assays.

• WNT5a/GSK3/β-catenin Axis Regulates Adipogenesis in Muscle F

  2026-05-15

  This study reveals that the WNT5a/GSK3/β-catenin signaling axis critically modulates adipogenic differentiation in skeletal muscle fibro/adipogenic progenitors (FAPs). By integrating pharmacological, single-cell, and in vivo approaches, the authors identify GSK3 inhibition and WNT5a signaling as pivotal in restraining fat infiltration in muscle tissue—highlighting potential targets for myopathy intervention.

• TMEM16F-Mediated Lipid Scrambling Suppresses Ferroptosis Exe

  2026-05-14

  Yang et al. reveal that TMEM16F-driven lipid scrambling on the plasma membrane is a critical suppressor of ferroptosis, directly influencing tumor immune rejection. By delineating the membrane remodeling events at the final stage of ferroptotic cell death, the study opens new opportunities for targeted cancer immunotherapy and mechanistic research into regulated cell death.

• OSMI-1 and Precision O-GlcNAc Transferase Inhibition: From A

  2026-05-14

  Explore the scientific depth of OSMI-1, a benchmark O-GlcNAc transferase inhibitor, with a unique focus on assay optimization and mechanistic relevance in O-GlcNAcylation research. Discover new insights for experimental design and translational applications.

• Re-evaluating ACE Inhibitor and Aminopeptidase Specificity

  2026-05-13

  Tieku and Hooper's study systematically compares the inhibitory profiles of bestatin, classic angiotensin converting enzyme (ACE) inhibitors, and other metallopeptidase inhibitors across aminopeptidase N, A, and W. Their findings clarify selectivity gaps critical for cardiovascular and renal disease research, informing the design of more targeted peptidase inhibition protocols.

• 3-Deazaneplanocin (DZNep): Enabling Precision in Translation

  2026-05-13

  This article offers a strategic, mechanistic, and evidence-based perspective on the deployment of 3-Deazaneplanocin (DZNep) as both a tool compound and translational lever in oncology. We connect mechanistic insights—the dual targeting of SAHH and EZH2—with experimental design and protocol optimization, while benchmarking DZNep’s value in apoptosis induction, cancer stem cell targeting, and hepatocellular carcinoma research. Drawing on recent literature and advanced workflows, we provide actionable guidance for translational researchers and highlight where this analysis advances beyond traditional product summaries.

• 3-Aminobenzamide (PARP-IN-1): Bridging Mechanism to Translat

  2026-05-12

  This thought-leadership article examines the strategic deployment of 3-Aminobenzamide (PARP-IN-1) for translational researchers, integrating mechanistic insights, rigorous protocol parameters, and cross-domain implications for cardiovascular, renal, and virology research. Building from new evidence on PARP-mediated immune modulation, we guide researchers toward impactful, reproducible experimentation with APExBIO’s 3-Aminobenzamide.

• Optimizing Cancer Research: LEE011 Succinate as a CDK Inhibi

  2026-05-12

  LEE011 succinate (Ribociclib succinate) stands out as a selective CDK inhibitor, empowering cancer researchers to execute precise cell cycle regulation and robust cell proliferation assays. This article provides actionable protocols, troubleshooting guidance, and advanced workflow strategies that leverage the unique properties of LEE011 succinate for translational oncology.

• Palonosetron for Chemotherapy-Induced Nausea: Mechanistic In

  2026-05-11

  This article examines the mechanistic and clinical advances of palonosetron hydrochloride as a 5-HT3 receptor antagonist for preventing chemotherapy-induced nausea and vomiting (CINV). By comparing palonosetron with earlier antiemetics, the review highlights its unique pharmacological properties and implications for oncology research and combination chemotherapy regimens.

• HotStart 2X Green qPCR Master Mix: Precision in Gene Analysi

  2026-05-11

  Unlock sensitive, reproducible real-time PCR gene expression analysis with the HotStart™ 2X Green qPCR Master Mix. Advanced antibody-mediated hot-start technology ensures specificity and robust performance, empowering translational workflows from neurobiology to toxicogenomics.

• Optimizing Cell Death Analysis with Annexin V-Cy5/DAPI Apopt

  2026-05-10

  The Annexin V-Cy5/DAPI Apoptosis Kit from APExBIO enables rapid, high-fidelity discrimination of apoptotic and necrotic cells—even in complex disease models like Philadelphia chromosome-positive acute lymphoblastic leukemia. This article breaks down real-world assay workflows, key mechanistic insights, and troubleshooting strategies to elevate your apoptosis detection and experimental reproducibility.

• Atomic Structures of FADD–Procaspase-8–cFLIP Complexes in Ap

  2026-05-09

  The reference study elucidates the atomic-level assembly of FADD, procaspase-8, and cFLIP complexes that govern death receptor-mediated apoptosis and necroptosis. These structural insights clarify how DED-based interactions determine cell fate decisions and provide a mechanistic foundation for targeted modulation of apoptosis in disease contexts.

• Bafilomycin C1: Precision V-ATPase Inhibitor for Advanced As

  2026-05-09

  Bafilomycin C1 stands apart as the gold-standard vacuolar H+-ATPases inhibitor, enabling rigorous dissection of autophagy, lysosomal trafficking, and intracellular pH regulation. Its proven performance in high-content, phenotypic screening—especially with iPSC-derived cells—empowers researchers to decode disease mechanisms and de-risk drug discovery at early stages.

• Dissecting Drug-Induced Growth Arrest and Cell Death In Vitr

  2026-05-08

  Schwartz (2022) presents a rigorous analysis of how anti-cancer drugs differentially affect cell proliferation and death in vitro, revealing that traditional viability metrics can obscure mechanistic distinctions. This work advances the field by proposing refined evaluation methods to distinguish growth inhibition from direct cytotoxicity, providing actionable insight for drug discovery and mechanistic studies.

• Prostaglandin E2 in Inflammation Research: Protocols & Innov

  2026-05-07

  Prostaglandin E2 (PGE2) is a cornerstone in inflammation research, powering assays from immune modulation to gastrointestinal mucosal protection. This guide delivers practical workflow enhancements, troubleshooting strategies, and unique insights inspired by recent network pharmacology advances—maximizing the value of high-purity PGE2 from APExBIO.

451 records 18/31 page Previous Next First page 上5页 1617181920 下5页 Last page